Inositol hexakisphosphate increases the size of platelet aggregates

The inositol phosphates, InsP5 and InsP6, have recently been identified as binding partners of fibrinogen, which is critically involved in hemostasis by crosslinking activated platelets at sites of vascular injury. Here, we investigated the putative physiological role of this interaction and found t...

Full description

Bibliographic Details
Main Authors: Brehm, M, Klemm, U, Rehbach, C, Erdmann, N, Kolšek, K, Lin, H, Aponte-Santamaría, C, Gräter, F, Rauch, B, Riley, A, Mayr, G, Potter, B, Windhorst, S
Format: Journal article
Language:English
Published: Elsevier 2018
_version_ 1797081196545441792
author Brehm, M
Klemm, U
Rehbach, C
Erdmann, N
Kolšek, K
Lin, H
Aponte-Santamaría, C
Gräter, F
Rauch, B
Riley, A
Mayr, G
Potter, B
Windhorst, S
author_facet Brehm, M
Klemm, U
Rehbach, C
Erdmann, N
Kolšek, K
Lin, H
Aponte-Santamaría, C
Gräter, F
Rauch, B
Riley, A
Mayr, G
Potter, B
Windhorst, S
author_sort Brehm, M
collection OXFORD
description The inositol phosphates, InsP5 and InsP6, have recently been identified as binding partners of fibrinogen, which is critically involved in hemostasis by crosslinking activated platelets at sites of vascular injury. Here, we investigated the putative physiological role of this interaction and found that platelets increase their InsP6 concentration upon stimulation with the PLC-activating agonists thrombin, collagen I and ADP and present a fraction of it at the outer plasma membrane. Cone and plate analysis in whole blood revealed that InsP6 specifically increases platelet aggregate size. This effect is fibrinogen-dependent, since it is inhibited by an antibody that blocks fibrinogen binding to platelets. Furthermore, InsP6 has only an effect on aggregate size of washed platelets when fibrinogen is present, while it has no influence in presence of von Willebrand factor or collagen. By employing blind docking studies we predicted the binding site for InsP6 at the bundle between the γ and β helical subunit of fibrinogen. Since InsP6 is unable to directly activate platelets and it did not exhibit an effect on thrombin formation or fibrin structure, our data indicate that InsP6 might be a hemostatic agent that is produced by platelets upon stimulation with PLC-activating agonists to promote platelet aggregation by supporting crosslinking of fibrinogen and activated platelets.
first_indexed 2024-03-07T01:11:09Z
format Journal article
id oxford-uuid:8d0daa9c-66f9-4822-ac7d-46432c312f5b
institution University of Oxford
language English
last_indexed 2024-03-07T01:11:09Z
publishDate 2018
publisher Elsevier
record_format dspace
spelling oxford-uuid:8d0daa9c-66f9-4822-ac7d-46432c312f5b2022-03-26T22:48:47ZInositol hexakisphosphate increases the size of platelet aggregatesJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:8d0daa9c-66f9-4822-ac7d-46432c312f5bEnglishSymplectic Elements at OxfordElsevier2018Brehm, MKlemm, URehbach, CErdmann, NKolšek, KLin, HAponte-Santamaría, CGräter, FRauch, BRiley, AMayr, GPotter, BWindhorst, SThe inositol phosphates, InsP5 and InsP6, have recently been identified as binding partners of fibrinogen, which is critically involved in hemostasis by crosslinking activated platelets at sites of vascular injury. Here, we investigated the putative physiological role of this interaction and found that platelets increase their InsP6 concentration upon stimulation with the PLC-activating agonists thrombin, collagen I and ADP and present a fraction of it at the outer plasma membrane. Cone and plate analysis in whole blood revealed that InsP6 specifically increases platelet aggregate size. This effect is fibrinogen-dependent, since it is inhibited by an antibody that blocks fibrinogen binding to platelets. Furthermore, InsP6 has only an effect on aggregate size of washed platelets when fibrinogen is present, while it has no influence in presence of von Willebrand factor or collagen. By employing blind docking studies we predicted the binding site for InsP6 at the bundle between the γ and β helical subunit of fibrinogen. Since InsP6 is unable to directly activate platelets and it did not exhibit an effect on thrombin formation or fibrin structure, our data indicate that InsP6 might be a hemostatic agent that is produced by platelets upon stimulation with PLC-activating agonists to promote platelet aggregation by supporting crosslinking of fibrinogen and activated platelets.
spellingShingle Brehm, M
Klemm, U
Rehbach, C
Erdmann, N
Kolšek, K
Lin, H
Aponte-Santamaría, C
Gräter, F
Rauch, B
Riley, A
Mayr, G
Potter, B
Windhorst, S
Inositol hexakisphosphate increases the size of platelet aggregates
title Inositol hexakisphosphate increases the size of platelet aggregates
title_full Inositol hexakisphosphate increases the size of platelet aggregates
title_fullStr Inositol hexakisphosphate increases the size of platelet aggregates
title_full_unstemmed Inositol hexakisphosphate increases the size of platelet aggregates
title_short Inositol hexakisphosphate increases the size of platelet aggregates
title_sort inositol hexakisphosphate increases the size of platelet aggregates
work_keys_str_mv AT brehmm inositolhexakisphosphateincreasesthesizeofplateletaggregates
AT klemmu inositolhexakisphosphateincreasesthesizeofplateletaggregates
AT rehbachc inositolhexakisphosphateincreasesthesizeofplateletaggregates
AT erdmannn inositolhexakisphosphateincreasesthesizeofplateletaggregates
AT kolsekk inositolhexakisphosphateincreasesthesizeofplateletaggregates
AT linh inositolhexakisphosphateincreasesthesizeofplateletaggregates
AT apontesantamariac inositolhexakisphosphateincreasesthesizeofplateletaggregates
AT graterf inositolhexakisphosphateincreasesthesizeofplateletaggregates
AT rauchb inositolhexakisphosphateincreasesthesizeofplateletaggregates
AT rileya inositolhexakisphosphateincreasesthesizeofplateletaggregates
AT mayrg inositolhexakisphosphateincreasesthesizeofplateletaggregates
AT potterb inositolhexakisphosphateincreasesthesizeofplateletaggregates
AT windhorsts inositolhexakisphosphateincreasesthesizeofplateletaggregates